Translate this page into:
Short Communication
PMID: 20952956
Itraconazole versus griseofulvin in the treatment of tinea corporis and tinea cruris
KM Acharya, Amiyakumar Mukhopadhyay, RK Thakur, T Mehta, Neela Bhuptani, Ramnik Patel
Department of Skin, STD and Leprosy, MP Shah Medical College and Irwin Group of Hospitals, Jamnagar - 36100, India
Correspondence Address:
K M Acharya
Department of Skin, STD and Leprosy, MP Shah Medical College and Irwin Group of Hospitals, Jamnagar - 36100
India
Correspondence Address:
K M Acharya
Department of Skin, STD and Leprosy, MP Shah Medical College and Irwin Group of Hospitals, Jamnagar - 36100
India
| How to cite this article: Acharya K M, Mukhopadhyay A, Thakur R K, Mehta T, Bhuptani N, Patel R. Itraconazole versus griseofulvin in the treatment of tinea corporis and tinea cruris. Indian J Dermatol Venereol Leprol 1995;61:209-211 |
Copyright: (C)1995 Indian Journal of Dermatology, Venereology, and Leprology
Abstract
126 patients (82 males and 44 females) aged above 12 years, suffering from tinea corporis and/or tinea cruris, were treated with either itraconazole (100 mg once a day for 2 weeks and then plecebo for 2 weeks) (63 patients), or griseofulvin (250 mg twice a day for 4 weeks). 90.47% of the patients treated with itraconzole improved whereas griseofulvin imporved 76.19% of patients, clinically. Mycological response was 72% with itraconazole and 57% with griseofulvin.
Keywords: Tinea corporis, Tinea cruris, Itraconazole, Griseofulvin
Fulltext Views
2,886
PDF downloads
1,505
